To establish the efficacy of PPI therapy for ulcer bleeding in the United States, do we need more patients or more PPIs?

Grigoris I. Leontiadis, Colin Howden

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Proton pump inhibitor (PPI) therapy is widely used in the management of patients with ulcer bleeding. However, most randomized controlled trials (RCTs) have been conducted outside of the United States. Jensen and colleagues have conducted the first United States-based RCT to compare a PPI with an H2-receptor antagonist following appropriate endoscopic hemostatic treatment for patients with ulcer bleeding. Unfortunately, the trial had to be discontinued prematurely because of problems with enrolment. There was a statistically nonsignificant difference in rebleeding rates between the two treatment arms. A type II statistical error probably explains this apparent lack of efficacy. However, U.S. patients may also require higher doses of PPI for adequate control of intragastric acidity.

Original languageEnglish (US)
Pages (from-to)2000-2002
Number of pages3
JournalAmerican Journal of Gastroenterology
Volume101
Issue number9
DOIs
StatePublished - Sep 1 2006
Externally publishedYes

Fingerprint

Proton Pump Inhibitors
Ulcer
Hemorrhage
Randomized Controlled Trials
Histamine H2 Receptors
Hemostatics
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

To establish the efficacy of PPI therapy for ulcer bleeding in the United States, do we need more patients or more PPIs? / Leontiadis, Grigoris I.; Howden, Colin.

In: American Journal of Gastroenterology, Vol. 101, No. 9, 01.09.2006, p. 2000-2002.

Research output: Contribution to journalReview article

@article{005f7ea79b0c43cea009d0f78390c4a6,
title = "To establish the efficacy of PPI therapy for ulcer bleeding in the United States, do we need more patients or more PPIs?",
abstract = "Proton pump inhibitor (PPI) therapy is widely used in the management of patients with ulcer bleeding. However, most randomized controlled trials (RCTs) have been conducted outside of the United States. Jensen and colleagues have conducted the first United States-based RCT to compare a PPI with an H2-receptor antagonist following appropriate endoscopic hemostatic treatment for patients with ulcer bleeding. Unfortunately, the trial had to be discontinued prematurely because of problems with enrolment. There was a statistically nonsignificant difference in rebleeding rates between the two treatment arms. A type II statistical error probably explains this apparent lack of efficacy. However, U.S. patients may also require higher doses of PPI for adequate control of intragastric acidity.",
author = "Leontiadis, {Grigoris I.} and Colin Howden",
year = "2006",
month = "9",
day = "1",
doi = "10.1111/j.1572-0241.2006.00786.x",
language = "English (US)",
volume = "101",
pages = "2000--2002",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - To establish the efficacy of PPI therapy for ulcer bleeding in the United States, do we need more patients or more PPIs?

AU - Leontiadis, Grigoris I.

AU - Howden, Colin

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Proton pump inhibitor (PPI) therapy is widely used in the management of patients with ulcer bleeding. However, most randomized controlled trials (RCTs) have been conducted outside of the United States. Jensen and colleagues have conducted the first United States-based RCT to compare a PPI with an H2-receptor antagonist following appropriate endoscopic hemostatic treatment for patients with ulcer bleeding. Unfortunately, the trial had to be discontinued prematurely because of problems with enrolment. There was a statistically nonsignificant difference in rebleeding rates between the two treatment arms. A type II statistical error probably explains this apparent lack of efficacy. However, U.S. patients may also require higher doses of PPI for adequate control of intragastric acidity.

AB - Proton pump inhibitor (PPI) therapy is widely used in the management of patients with ulcer bleeding. However, most randomized controlled trials (RCTs) have been conducted outside of the United States. Jensen and colleagues have conducted the first United States-based RCT to compare a PPI with an H2-receptor antagonist following appropriate endoscopic hemostatic treatment for patients with ulcer bleeding. Unfortunately, the trial had to be discontinued prematurely because of problems with enrolment. There was a statistically nonsignificant difference in rebleeding rates between the two treatment arms. A type II statistical error probably explains this apparent lack of efficacy. However, U.S. patients may also require higher doses of PPI for adequate control of intragastric acidity.

UR - http://www.scopus.com/inward/record.url?scp=33748373180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748373180&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.2006.00786.x

DO - 10.1111/j.1572-0241.2006.00786.x

M3 - Review article

VL - 101

SP - 2000

EP - 2002

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 9

ER -